BioRegenx, Inc.
BRGX
$0.01
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 90.11% | 94.47% | 79.59% | 83.88% | 91.53% |
| Total Depreciation and Amortization | 4.03% | -93.40% | -102.19% | -93.44% | -97.52% |
| Total Amortization of Deferred Charges | -- | -254.32% | 213.95% | -108.82% | -86.61% |
| Total Other Non-Cash Items | -151.48% | -95.15% | 132.59% | -60.78% | -96.02% |
| Change in Net Operating Assets | -56.30% | 58.17% | -319.71% | -51.43% | -18.69% |
| Cash from Operations | -29.44% | 710.53% | -129.49% | 101.80% | 136.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Investing | -- | -214.81% | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | 106.87% | -77.29% | -- |
| Total Debt Repaid | -438.46% | -418.82% | -353.40% | -10.00% | 40.23% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -382.69% | -539.13% | 52.59% | -86.01% | -103.68% |
| Foreign Exchange rate Adjustments | -- | -100.00% | 376.92% | -1,540.00% | -310.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.65% | 291.45% | -96.06% | 34.51% | 325.00% |